REQUEST A DEMO
Total
USD $0.00
Search more companies

Pharmaswiss D.O.O. (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Pharmaswiss D.O.O. Beograd Profile Updated: March 14, 2019
Buy our report for this company USD 29.95 Most recent financial data: 2017 Available in: English Download a sample report

Swiss pharmaceutical company PharmaSwiss set up its Serbian unit in 2001. The Belgrade-based company is active in the wholesale and manufacture of pharmaceuticals and pharmaceutical products. It is an exclusive distributor and representative of Bristol Myers Squib, Ibsen, Wyeth-embrel, Reckitt Benckiser, Amgen, Astelas, Aspen, Lannacher, Mika Pharma and Eli Lilly.

Headquarters
Batajnicki drum 5A
Belgrade; Belgrade; Postal Code: 11010

Contact Details: Purchase the Pharmaswiss D.O.O. report to view the information.

Website: http://pharmaswiss.rs

Basic Information
Total Employees:
Purchase the Pharmaswiss D.O.O. report to view the information.
Registered Capital:
Purchase the Pharmaswiss D.O.O. report to view the information.
Financial Auditors:
Purchase the Pharmaswiss D.O.O. report to view the information.
Incorporation Date:
February 27, 2001
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Procurator
Purchase this report to view the information.
Procurator
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Emitobanje Televizijskog I Radio Programa Rtl Tv D.O.O.Beograd - U Likvidaciji
10%
Company Performance
Financial values in the chart are available after Pharmaswiss D.O.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
5.1%
Total operating revenue
5.1%
Operating profit (EBIT)
8.19%
EBITDA
8.9%
Net Profit (Loss) for the Period
162.1%
Total assets
-11.72%
Total equity
26.6%
Operating Profit Margin (ROS)
0.5%
Net Profit Margin
9.86%
Return on Equity (ROE)
10.86%
Quick Ratio
0.57%
Cash Ratio
0.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?